


INTENSITY-HIGH

Investigating the lowest Threshold of vascular bENefits from LDL cholesterol lowering with a PCSK9 mAb InhibiTor (alirocumab) in patients with stable cardiovascular disease - (INTENSITY-HIGH)



**Would you like to help with
medical research?**

**Are you a male or female aged 40 years and
above who suffers from Cardiovascular Disease?**

If so you may be eligible!

This study is investigating the effects of lowering LDL Cholesterol ('Bad Cholesterol') and determining what benefits this has on improving vascular function

If you think you may be interested and would like additional information about the study, please contact our research team:

Contact: Dr Paul Cacciottolo

Tel: 01223 911806



Email: pjc99@medschl.cam.ac.uk

You will be reimbursed any travel and parking expenses as a result of participating in this study and you will be paid on a pro-rata basis up to £500 as an honorarium for your participation and completion of the study.